Related Experiment Video

Updated: Dec 30, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K

[Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis]

Y M Nan1, L D Liu, W Zhao

  • 1Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.

Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|January 17, 2020
PubMed

Insights

Direct-acting antiviral agents (DAAs) offer a safe treatment for hepatitis C virus-related decompensated cirrhosis. Sofosbuvir-based regimens achieve high sustained virological response rates and improve liver function, reducing transplant needs.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Direct-acting antiviral agents (DAAs) are primary treatments for hepatitis C virus (HCV)-related decompensated cirrhosis.
  • NS3/4A protease inhibitors are not recommended due to liver metabolism.
  • Recent guidelines favor sofosbuvir (SOF)-based regimens.

Purpose of the Study:

  • To evaluate the efficacy and safety of SOF-based DAAs in patients with HCV-related decompensated cirrhosis.
  • To assess the impact of DAAs on liver function and the need for liver transplantation.

Main Methods:

  • Review of SOF-based regimens including SOF/velpatasvir, SOF/daclatasvir, and SOF/ledipasvir.
  • Analysis of sustained virological response (SVR) rates at 12/24 weeks.
  • Evaluation of liver reserve function improvement and reduction in liver transplantation requirements.

Main Results:

  • SOF-based regimens achieve high SVR rates (88%–100%).
  • Significant improvement in liver reserve function observed in 42%–53% of patients.
  • Reduced need for liver transplantation, with 15.5%–49% avoiding it short-term and 10.3%–19.2% specifically with SOF/LDV or SOF/DCV.

Conclusions:

  • SOF-based DAAs represent a safe and effective antiviral strategy for HCV-related decompensated cirrhosis.
  • These treatments improve patient outcomes and decrease the burden on liver transplantation waiting lists.

Keywords:
Decompensation of liver functionDirected-acting antiviral agentsHepatitis C virusLiver cirrhosis

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.7K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
172
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
205
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
137
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.0K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
318
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
256